Category Biotechnology
Gb Sciences Granted U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary Cystitis
This new patent covers receptor-targeted formulations for the treatment of cardiac hypertrophy, TRPV1-receptor-associated hearing loss and urinary cystitis.
Read Press Release
Neurocentria Obtains FDA Approval to Conduct Pivotal Phase IIb/III Clinical Trial for Testing Safety and Efficacy of Drug Candidate NRCT-101SR in Adults With ADHD
Novel NRCT-101SR shown in previous human studies to be effective and well-tolerated with no side effects
Read Press Release
Faro Health Inc. Expands Leadership Team and Announces Participation at SCOPE, Following Its $15 Million Series A Funding
● Faro Health Inc. strengthens its management team, appointing Kimberly C. Pospahala as Vice President of Commercial to accelerate go-to-market efforts to digitally transform clinical protocol design ● Scott Chetham, Ph.D., Co-Founder & CEO of Faro Health, Inc., will present at the SCOPE Conference on Feb. 9, 2022
Read Press Release
Gb Sciences and Michigan State University Researchers Have Identified the Complicated Truth Behind the Opportunity for an Effective Cannabinoid-Based Coronavirus Treatment
Gb Sciences' collaboration with MSU has received media coverage across the country, starting with an interview from WLNS-TV in Lansing, Michigan, and interviews with Gb Sciences in the magazines 'Cannabis Business Times' and 'Hemp Grower'
Read Press Release
